ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.

Envista raises 2026 guidance as stronger sales and expanding margins lift earnings, but China pricing, tariffs and a tougher Q4 loom.

BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

ALGN highlights record clear aligner volumes, digital workflow expansion and margin gains while balancing scanner pricing pressures and long-term growth plans.

While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Align Technology (ALGN) delivered earnings and revenue surprises of +3.13% and +0.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ALGN's global expansion and iTero innovations support growth, but can they offset currency headwinds and macro pressures?